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Summary. Thrombopoietin (TPO) immunogenicity ham-
pers its development as a therapeutic agent for attenuating
thrombocytopenia and improving platelet harvest in
donors. This work was aimed at validating, in mouse and in
monkey experiments, a thrombopoiesis computer-model
prediction that platelet counts, similar to those obtained
with accepted TPO dose scheduling, can also be achieved by
new and safer schedules of significantly reduced doses. To
this end we compared, in a two-arm mouse experiment,
platelet increases obtained with a single intraperitoneal
dosing of recombinant mouse TPO (17Æ5 lg/kg), with those
obtained by the model-suggested protocol of a significantly
reduced dose (2 lg/kg on 4 consecutive days). The two TPO
regimens generated similar platelet profiles, peaking at
ca. 2700 · 109/l platelets. In rhesus monkeys, treated by
rhesus monkey recombinant TPO (5 lg/kg on 4 consecu-
tive days), the suggested protocol yielded effective platelet
stimulation with significantly reduced immunogenicity. The
model’s ability to predict individual monkey responses to
several new TPO administration protocols was further val-
idated, proving sufficient robustness in providing good pre-
dictions with limited input data. The simulation tool could
be used for testing the effects of different therapeutic agents
on thrombopoiesis. Human trials are warranted for testing
the suggested improved TPO protocol, possibly in conjunc-
tion with chemotherapy.
Keywords: thrombopoiesis, immunogenicity, thrombopoietin,
modelling, treatment schedule.
Thrombocytopenia poses a major clinical problem in the
management of haematology and oncology patients and
contributes significantly to morbidity and mortality in
cancer patients (Demetri, 2001). In addition, it limits cancer
therapy by preventing the administration of drugs at
optimal doses and schedules (Demetri, 2001; Elting et al,
2001). Repeated transfusions may aid in preventing bleed-
ing, but increase the risk of pathogen transmission and
transfusion reactions, as well as health care costs and
inconvenience to patients. For these reasons, an agent that
stimulates platelet production is greatly significant in
preventing or attenuating thrombocytopenia, as well as in
improving the efficacy of platelet harvesting in donors
(Haznedaroglu et al, 2002).
Several recombinant or synthetic thrombopoiesis-stimu-
lating agents currently exist. These agents are derived from
the naturally occurring cytokine with thrombopoietic
activity, thrombopoietin (TPO) (Vadhan-Raj, 1998; Harker,
1999). However, an efficient method for defining drug
schedules, which maximizes these agents’ therapeutic
benefits and minimizes adverse complications, is yet to be
established (Neelis et al, 1998).
Recently, a detailed mathematical model of thrombopoi-
esis has been put forward (Skomorovski & Agur, 2001). The
model breaks down thrombopoiesis into 11 developmental
compartments from stem cells to peripheral blood platelets.
It takes into account the intrinsic cellular dynamics in each
compartment, as well as the detailed kinetic effects of
endogenous and exogenous TPO. The model is integrated in
a computer tool to simulate momentary in vivo effects of
drug administration schedules on the peripheral platelet
levels and on cell counts in each of the different bone
marrow compartments. Using published data (Vadhan-Raj
et al, 1997; Miyazaki et al, 1999), the model’s ability to
retrieve post-TPO-treatment platelet profiles in patients has
been retrospectively validated (Skomorovski & Agur, 2001).
The use of recombinant human TPO as a therapeutic
agent has been stalled by safety and efficacy complications
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caused by the immunogenicity of a recombinant variant,
megakaryocyte growth and development factor (MGDF)
(Basser, 2002). Therefore, the present work was aimed, first
and foremost, at preclinically validating the model-sug-
gested new TPO regimen of improved efficacy and reduced
immunogenicity. In addition we wished to validate, under
various levels of prior empirical information, the thrombo-
poiesis model’s ability to accurately predict an individual’s
response to different drug schedules.
MATERIALS AND METHODS
Mouse experiments
Animals. BALB/c male mice, approximately 12 weeks of
age and weighing about 25 g at the time of the study
initiation, were acclimatized for at least 5 d before the study
initiation. Eight groups of five mice each were used. All test
animals were kept under environmentally controlled hous-
ing conditions throughout the entire study period.
Test agents. Recombinant mouse TPO (rmTPO) was
kindly supplied by Genentech Inc., South San Francisco,
CA, USA. Full-length TPO was produced by Chinese
hamster ovary (CHO) cells, dissolved in phosphate-buffered
saline (PBS)/0Æ01% Tween 20 (denoted vehicle) at a
concentration of 0Æ375 mg/ml and stored in 1 ml vials at
4C. The purity was >99%. Before in vivo administration,
the drug was diluted in PBS/0Æ01% Tween 20 to the
appropriate concentration. PBS/0Æ01% Tween 20 was used
as placebo. Both the test material (TPO) and the vehicle
were administered by intraperitoneal injection. All treat-
ments were administered at the same hour, and the
volume of single intraperitoneal injections was 20 ml/kg.
Blood sampling. Blood samples were collected at a similar
daily hour by puncture of the retro-orbital plexus using a
micro-haematocrit capillary tube. Blood was transferred to
tubes with ethylene diamine tetra-acetic acid (EDTA), and
delivered at room temperature (RT) to the laboratory.
Complete blood cell counts were measured using a Sysmex
F-800 haematology analyzer (Toa Medical Electronics Co.,
Ltd, Kobe, Japan). The volume of individual blood samples
collected from test animals did not exceed 150 ll per sample.
Serial observations. Observations for any adverse effects of
the treatment were carried out at least once daily through-
out the entire study period.
Study design. Mice were randomly assigned to two arms.
Mice in arm A received a single bolus intraperitoneal
injection of 17Æ5 lg/kg rmTPO. Mice in arm B received a
total dose of 8 lg/kg, divided over four daily intraperitoneal
injections of 2 lg/kg rmTPO. Animals in control group
received vehicle only or no treatment at all. To enable blood
sampling on days 5, 6 and 7 (days of suggested platelet
peak), and on days 10 and 11 (days of suggested return to
baseline), each arm was subdivided into three groups,
which were sampled for subsequent haematological analysis
as follows: one group from each arm was sampled on days 5
and 10, another on days 6 and 11, and the third on day 7.
The placebo group was sampled on days 5 and 11. The
group of no treatment was sampled on days 0 and 11 in
order to determine the baseline platelet counts.
Statistics. Final evaluation of the results was primarily
based on determining the comparable changes in the level
of thrombocytes in animals of the treatment groups versus
that of the vehicle control group. Standard deviations were
calculated assuming a Gaussian distribution. The Wilcoxon
Two-Sample Rank test was performed to determine the
similarity of the platelet peak values.
Rhesus monkey experiments
Animals. Purpose-bred male rhesus monkeys (Macaca
mulatta), weighing 2Æ5–4Æ0 kg and aged 2–3 years were
used. The monkeys were housed in groups of four to six in
stainless steel cages in rooms equipped with a reverse
filtered air barrier, normal day light rhythm and condi-
tioned to 20C with a relative humidity of 70%. Animals
were fed ad libitum with commercial primate chow and fresh
fruits, and received acidified drinking water. All animals
were free of intestinal parasites and seronegative for herpes
B, hepatitis B, simian T-lymphotropic viruses and simian
immunodeficiency virus. Housing, experiments and all
other conditions were approved by an ethical committee
in accordance with the legal regulations in The Nether-
lands.
TPO administration. Vials of 1 ml, containing 0Æ930 mg/
ml recombinant full-length rhesus monkey TPO produced
by CHO cells were supplied by Genentech Inc. A dose of
5 lg/kg was diluted to a volume of 1 ml with PBS/0Æ01%
Tween 20 before administration. TPO was administered
subcutaneously. Because of previously demonstrated iron
deficiency after TPO administration (Neelis et al, 1997a),
the monkeys received iron supplementation; 0Æ5 ml Imferon
intramuscularly [Fe(III) 50 mg/ml; Fisons Pharmaceuticals,
Loughborough, England] alternately in the left or right
thigh, simultaneously with the growth factor administra-
tion.
Haematological examinations. Complete blood cell counts
were measured in EDTA-anticoagulated blood between 8
and 9 am using a Sysmex F-800 haematology analyzer (Toa
Medical Electronics Co.). Serum was collected weekly and
frozen at )20C.
Detection of TPO antibodies (Abs). The concentration of
anti-TPO Abs was measured by using a sensitive enzyme-
linked immunosorbent assay (ELISA) with a detection limit
of 10 pg/ml. Microtitre Covalink 96 wells plates (Nunc,
Rockslide, Denmark) were activated by treatment with a
dithiobis (succinimidyl proprionate) (Pierce, Rockford, Illi-
nois, USA) solution in methanol, for 30 min at RT.
Afterwards, wells were incubated with 50 ll (1 lg/ml)
recombinant full-length rhesus monkey TPO produced by
CHO cells (Genentech Inc.) in PBS (pH 7Æ4) for 2 h at RT.
Non-specific binding sites were blocked with a PBS–albumin
solution (1% bovine serum albumin; A7030, Sigma,
Zwijndrecht, The Netherlands), 250 ll per well, and plates
were stored overnight at 4C. Before use, plates were
washed six times with 200 ll PBS/Tween-20 (0Æ05%)
solution at RT. Subsequently, 50 ll serum 1/100 diluted
in PBS–Tween-1% BSA was added to the wells and the
plates were incubated for 1 h at RT. After six washes,
rabbit-anti-rhesus-Ig-PO (A2054, Sigma) diluted 1/35 000
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according to the manufacturer’s instructions, was added,
followed by an incubation of 1 h at RT. After incubation,
the wells were washed six times with 200 ll PBS/Tween
solution and 100 ll 3,3¢,5,5¢-tetramethylbenzidine- sub-
strate (Kirkegaard and Perry Laboratories, Maryland) was
added. All incubations were performed while shaking the
plates gently using an INNOVA 2100 platform shaker (New
Brunswick Scientific, Nijmegen, the Netherlands) set at
75 r.p.m. The colorimetric reaction was stopped by addition
of 100 ll 1 mol/l ortho-phosphoric acid (Merck, Darmstadt,
Germany) and the absorbance at 450 nm was measured in
a microplate reader (Bio-Rad Laboratories Inc., Hercules,
CA, USA). For comparison, a dose response curve was
incorporated in each experiment by coating a set of wells
with rHuman TPO and one with rRhesus TPO, incubating
with dilutions of mouse monoclonal anti-
Human-TPO (R & D systems, Minneapolis, MN, USA) and
detected with a 1/10 000 dilution of GAM-PO (A8924,
Sigma). Samples were measured in quadruplicate. The
results are expressed as optical density (OD).
Study design. In the first stage of this experiment, each of
the five monkeys received a different individual TPO
schedule (Fig 1A). Blood samples were drawn for blood
counts and serum Abs against TPO. In the second stage,
two other monkeys were each given a schedule of four daily
doses of TPO (5 lg/kg per dose), implementing the same
regimen as in mice (Fig 1B).
Thrombopoiesis computer model
The computer model employed in this work (Skomorovski &
Agur, 2001) consists of a comprehensive and very detailed
mathematical description of thrombopoiesis, from the level
of stem cells, to the level of platelets in the blood. The precise
description of the model’s many equations is beyond the
scope of this report, but its general structure is represented
in Fig 2 and its basic assumptions are detailed hereafter.
As shown in Fig 2, the model comprises 11 compart-
ments comprehensively describing thrombopoiesis. The first
nine represent the different stages of bone marrow cell
progression. The 10th compartment represents the mature
platelets in peripheral blood. Each of these 10 compartments
is further sub-divided according to the maturation stage
(age) of the cells in it. An additional 11th compartment
represents TPO concentration in the blood.
Mathematically, the thrombopoiesis model is discrete in
time and is formulated through delay difference equations
(DDEs). The exact state of the system at any time-step is
represented through the momentary distributions of cell
numbers in each compartment, so that each cell in each
subpopulation within a given compartment is characterized
by two indices: calendar time and age. In addition, the model
includes functions describing the kinetic characteristics of
cells in the different compartments, such as compartmental
transit time, the rate of cell flow from one compartment to
the next, the duration of megakaryocytes’ endomitosis, and
platelet release rate from mature megakaryocytes.
The model assumes that blood platelets are eliminated in
two ways: age-independent, through normal consumption
by the body (e.g. clotting), and age-dependent, kinetically
characterized by a ‘transit time’ in the blood. The model
includes TPO pharmacokinetics (PK), consisting of produc-
tion by the body, absorption of exogenous TPO, consump-
tion by cells, and other mechanisms of clearance. It also
includes TPO pharmacodynamics (PD) characteristics,
namely, the effects of TPO on the kinetic parameters of
cells in the above mentioned cellular compartments.
Parameter adjustment module
Iterative adjustment of biological and PK/PD parameters
was performed within the range of potential real-life values,
so as to most accurately retrieve the experimental results.
The module used the thrombopoiesis simulation model
(described above), an empirical platelet profile of one rhesus
monkey (monkey no. 5) treated by TPO (see Fig 1 for
protocol details), and an efficient search algorithm (e.g.
modified Powell’s conjugate directions method) (Brent,
1973; Press et al, 1993; unpublished observations).
Calibration of the thrombopoiesis computer model
Parameter calibration was performed in order to fine-tune
the model to thrombopoiesis of the species in question. It
involved definition of a biologically realistic range of values
for each parameter in murine thrombopoiesis (Ebbe &
Stohlman, 1965; Schermer, 1967; Siegers et al, 1979;
Kaushansky et al, 1996; Arnold et al, 1997; Ulich et al,
1999; Luoh et al, 2000) and simian thrombopoiesis (Farese
et al, 1995; Harker et al, 1996a,b; Neelis et al, 1997b;
Wagemaker et al, 1998; De Serres et al, 1999; Sola et al,
2000), which were then entered as the initial input for the
Fig 1. Thrombopoietin (TPO) administration schedules to monkeys.
Each triangle represents a dose of 5 lg/kg recombinant full length
rhesus monkey TPO. (A) Five different protocols of the five monkeys
studied. (B) Identical protocols of the two monkeys of the second
group. Each of these monkeys was subsequently treated with the
same schedule for two additional times with similar platelet
responses, and did not develop neutralizing antibodies (Abs) (data
not shown, unpublished observations).
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fine-tuning process. Thus, the set of model parameters, best
fitting the available empirical results of the species in
question was identified by multiple curves fitting within the
above ranges.
RESULTS
Similar platelet peaks can be obtained under significantly varying
TPO schedules – validation in mice
We checked in mice the model’s prediction that platelet
counts, similar to those achieved with the accepted protocol,
can be also generated under different schedules, of appre-
ciably reduced TPO doses. Hence, two different administra-
tion schedules were applied to mice of the two experiment
arms and their subsequent responses were compared. As
this experiment was aimed at demonstrating improved
efficacy (i.e. higher platelet yield per TPO unit) of a newly
suggested TPO schedule, it was imperative that similarity in
platelet yields reflect actual similarity between the dose
schedules effect on platelet count, rather than both sched-
ules merely driving platelet counts to saturation.
In mice, a maximum elevation in platelet blood count, in
response to a single dosing, of about five- to six-fold above
baseline was observed following the administration of
250 lg/kg pegylated recombinant murine MGDF (PEG-
rmMGDF), equivalent to ca. 2500 lg/kg non-PEG-rmMGDF
(Daw et al, 1998). Based on this information, mice in the
first arm received a single injection of 17Æ5 lg/kg rmTPO,
well below the above reported saturating level. The second
arm tested the model-generated proposition that the same
platelet yields can be obtained in mice receiving a total dose
of 8 lg/kg rmTPO, divided over four equal daily injections,
whereas the null hypothesis was that a significantly smaller
total dose of rmTPO would be less efficient in elevating the
platelet counts.
The platelet profile of arm A, in which the mice received a
single dose of 17Æ5 lg/kg rmTPO, was similar to the profile
of arm B, in which the mice received a total dose of 8 lg/kg,
divided over four equal daily fractions (Fig 3A). The
differences were not statistically significant (Student’s
t-test). The average profiles of both arm A and B peaked
at approximately the same time (day 5 vs. day 6 respect-
Fig 2. A scheme of the thrombopoiesis computer model. The first 10 compartments are: SC, stem cells; CFU, colony forming units; MKB (4, 8
and 16), megakaryoblasts (of ploidies 4 N, 8 N and 16 N respectively); MK (16, 32, 64 and 128), megakaryocytes (of ploidy 16 N, 32 N, 64 N
and 128 N respectively); and PL, platelets. The 11th compartment is indicated by the letters ‘TPO’. Relevant key parameters included in the
kinetic calculations of the different compartments are denoted as follows: rep, amplification rate; flowon, flow-on fraction; tr time, transit time;
and release rate, rate of platelet release. The perpendicular compartmental subdivisions represent cell-age transition. The arrows indicate the
direction of inter-compartmental cell flow.
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ively) and at similar mean platelet counts of
2741 ± 193 · 109/l and 2685 ± 164 · 109/l respectively.
The latter schedule resulted in slightly extended thrombo-
cytosis. Mean platelet volume (MPV), which is known to
decrease in thrombocytosis induced by low-dose TPO in
mice (Kabaya et al, 1996), was also compared between arm
A and arm B (Fig 3B). Results show that the familiar
phenomenon of MPV decrease also occurred to a similar
extent in both groups. Again, arm A preceded arm B in
reaching its nadir by about 24 h (6Æ76 fL on day 6 vs. 6Æ74
on day 7 respectively). Specific adverse effects were not
observed following either treatment.
Testing the predictions of the thrombopoiesis model in monkeys
In order to evaluate the efficacy of the treatment regimen in
monkeys, already validated in mice, we first checked the
ability of the thrombopoiesis simulation model to predict
individual monkey responses to different TPO treatments.
Subsequently, we simulated monkey responses to the
model-suggested protocol and compared our prediction
with the platelet counts obtained in vivo.
To check the simulation model’s ability to predict
individual responses to different drug schedules, the model’s
parameters were customized to accurately retrieve the
platelet profile of one specific individual from the monkey
experimental group. Next, the model was applied to predict
the responses of other monkeys in the same group to new
dosing regimens. The underlying assumption is that mem-
bers of a subpopulation, similar in genetic background as
well as in environmental conditions, will also have a similar
response to TPO treatment.
First we fine-tuned the model’s parameters to fit one
monkey empirical platelet profile. The quantitatively ade-
quate simulation of thrombopoiesis response to treatment
was apparent from its resemblance to the empirical results
(Fig 4). This calibrated model was further applied to predict
the profiles of the other four monkeys, which had each
received a different drug protocol (see protocols in Fig 1A).
The model’s predictions for monkeys no. 1, 2 and 4 were
remarkably close to the empirical data-points (Fig 5). Note
that, as the platelet counts were monitored in these
monkeys only once weekly, an a priori mismatch is
introduced into the comparison between the empirical
results and the daily predicted counts. Therefore, there is
no reason to assume that the peaks in the predicted
responses on days that were not tested empirically, did not
actually take place (days 11 and 25 in monkey no. 1, days
15 and 32 in monkey no. 2, and days 11 and 21 in monkey
no. 4). In contrast, the large discrepancy between the
predicted and the empirical results of monkey no. 3 (Fig 6)
cannot be accounted for by the resolution difference
between real-life monitoring and the simulations. This
monkey became rapidly refractory to TPO treatment, as a
result of undue formation of neutralizing Abs. Monkeys no.
1 and 2 also developed an antibody response that neutral-
ized endogenous TPO upon a subsequent boost with
exogenous TPO (unpublished observations), however not
within the time frame displayed in Fig 1A. The model’s
predictive ability was further challenged when the present
calibration was employed for predicting responses to TPO of
another group of monkeys.
Fig 3. (A) Daily platelet counts and (B) MPV measurements, of
mice treated with thrombopoietin (TPO). Comparison is between a
‘conventional’ single dose treatment (arm A, solid triangles) and a
model-suggested reduced dose treatment (arm B, open squares) and
a control group (solid circles); average ± SD of five mice is shown,
per each entry. Day 0 is the day of TPO treatment initiation. Mice in
arm A received a single dose of 17Æ5 lg/kg TPO; mice in arm B
received 4 daily doses of 2 lg/kg TPO each, a total of 8 lg/kg.
Fig 4. Empirical versus simulated platelet counts of monkey no. 5
in response to thrombopoietin (TPO) treatment. Fourteen daily
doses of 5 lg/kg TPO were administered (administration days
marked by triangles). Measurements were performed daily (rec-
tangles), simulation results are indicated by a solid line.
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A safer TPO schedule – model validation in monkeys
The model-based regimen validated in mice was then
evaluated for efficacy and safety in two monkeys, each
undergoing three treatment cycles (see protocol in
Fig 1B). The resulting elevation in platelet counts peaked
at 1700–2400 · 109/l following each treatment cycle.
The results of the second cycle were similar to those of
the first in showing no neutralizing Abs. Only when the
dose schedule was applied for the third time, were very
low Ab titres detectable, which did not jeopardize TPOs
efficacy and did not result in decreased platelet counts
(unpublished observation). The individual empirical
responses of the two monkeys to the first treatment cycle
are shown in Fig 7, as compared with the model
predicted response. The empirical onset of platelet count
elevation preceded the predicted one by 2 d. The platelet
count peak was around day 8 in both observed and
predicted results, with similar measured peaks of ca.
1700 · 109 platelets/l, compared with a predicted peak of
ca. 1600 · 109 platelets/l. However, it is important to
note that the baseline counts of these two monkeys
(about 420 · 109 platelets/l) were not taken into
account: The present model calibration was performed
based on the previous baseline count (about 280 ·
109 platelets/l; Figs 4–6). Hence, the predictions of these
two monkeys were biased towards lower expected platelet
counts. Abs to TPO were not detected in the monkeys
treated in this experiment. A significant descent began on
Fig 5. Empirical versus simulated platelet counts. Platelet counts of
monkeys no. 1, no. 2 and no. 4 (A, B and C respectively) in response
to multiple dosing treatments by 5 lg/kg thrombopoietin doses
(administration day marked by a triangle). Measurements were
performed weekly or biweekly (rectangles); simulation results are
indicated by a solid line.
Fig 6. Platelet counts of monkey no. 3 in response to multiple
dosing treatment with 5 lg/kg thrombopoietin doses (administra-
tion days marked by triangles). Measurements were performed
about once weekly (rectangles); simulation results are marked by a
solid line. Antibody titre readings are shown as open circles.
Fig 7. Comparison between predicted and empirical responses of
monkeys to the suggested thrombopoietin (TPO) treatment. The
model predictions (line only) and empirical platelet profiles of
monkeys A and B (solid squares and circles respectively) are pre-
sented. TPO was administered as four daily doses of 5 lg/kg each
(administration days marked by triangles). The model’s predictions
were generated under the assumption of a baseline level of
280 · 109 platelets/l in the simulated monkeys (see also text).
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day 13 in the predicted result with a return to baseline
counts on day 20 in both, yet it was more gradual in the
empirical results.
DISCUSSION
The main purpose of this work was to validate the model-
generated prediction that a fractionated regimen of reduced
total TPO dose and an optimally spaced administration will
maintain TPO efficacy and eliminate its immunogenic side
effects. We showed here for the first time that it is possible to
retrieve quantitative biomathematical model predictions,
enabling suggestion of improved clinical treatments.
For the purpose of this validation we first showed in a
mouse experiment that two schedules of TPO administra-
tion, which differed significantly in total dose, did not differ
in efficacy. The empirical results (Fig 3A) exhibited highly
significant similarity between the platelet profiles of mice in
the two treatment groups. As the change in MPV, an
indicator of platelet production kinetics, was also similar in
both arms (Fig 3B), we infer that very similar stimuli were
received by the thrombopoietic system. Thus, the use of
smaller doses with an interval of 24 h, suggested by the
model predictions, proved equal in effect to the more than
double dose, administered as a bolus injection. This experi-
ment joins previous in vivo experiments with other drugs in
verifying a mathematical theory, which essentially suggests
that treatment efficacy can be decisively influenced by
modulating the inter-dosing interval according to the
internal cell kinetics (Agur et al, 1988; Agur et al, 1991;
Ubezio et al, 1994).
The monkey experiment supports the model prediction
of an equally efficient and non-immunogenic treatment, if
dose is fractionated by an appropriate dosing interval. The
model-suggested protocol has been administered to mon-
keys in three cycles at 3- to 4-month intervals. The
treatment showed high efficacy with no effective neutral-
izing antibody response. Note that an equal total dose,
delivered as a single bolus injection of 20 lg/kg, may be
similarly effective in avoiding immunogenicity. Neverthe-
less, based on the mouse experiment, this one bolus
protocol is expected to be less effective. Therefore,
although, a priori, from a clinical point of view, it may
not seem beneficial to the patient to replace a single
injection with four, it may be important for safety
considerations. A current modelling effort quantifies anti-
body formation as a result of TPO administration. This
could enable the design of effective drug administration
protocols with minimized immunogenicity.
In addition to validating the model-suggested improved
TPO protocol, we also validated the monkey thrombopoiesis
model and its predictions of individual responses to different
TPO regimens. These validations were performed assuming
that a genetically homogeneous group of animals that are
subject to the same laboratory conditions will show similar
responses. However, such a group is prone to expected
variability as a result of extrinsic factors as well as intra-
group variability. In the case of the monkeys, there was
some variation in age and weight (data not shown).
Nevertheless, the results of the predicted versus the meas-
ured response to TPO in monkeys no. 1, no. 2 and no. 4,
which were not compromised by a rapid antibody response,
showed a high accuracy of the model’s predictions
(Fig 5A–C), and suggest that the contribution of intra-
group variation to the overall TPO effect on platelet counts
is of relatively minor significance.
In order to predict the results of an additional group of
monkeys that were subject to a new TPO protocol (Fig 7),
the rhesus monkey tool, calibrated to simulate the above
group of five monkeys, was implemented. In the case of
this additional group, the tool’s predictive ability was
more accurately verified, as it was challenged by the
additional inter-group variability as well as by the daily-
monitored blood counts leading to higher empirical
precision. Nevertheless, the predicted response was very
similar to the empirical one in time and magnitude of
peak platelet levels.
It is of note that in the latter simulations we used the
original baseline setting of the first monkey validation
(280 · 109/l) instead of the actually measured baseline
levels (420 · 109/l). As the model correctly predicted time
and magnitude of the response, it turned out to be
sufficiently robust to provide predictions with limited input
data (in this case, data of only a single monkey, no. 5, for
which daily measurements were available).
Kinetic differences were observed between the monkeys’
experimental results and the model’s predictions (Fig 7).
The observed results showed an earlier onset of platelet
count elevation, an earlier decline from the observed peaks
and a less abrupt return to normal levels. Such differences
may result from inaccurate estimates of a few, or even of a
single kinetic parameter among the many implemented in
the model (e.g. transit time, platelet elimination rate, etc.),
as fine-tuning of the full process kinetics was based on the
kinetics of only one monkey (no. 5). It is anticipated that
input data from more monkeys will further improve the
model adjustment, to the extent that these minor deviations
will also be resolved.
Human validation of the thrombopoiesis computer tool
incorporating the effects of chemotherapeutic drugs is
underway. Once adjusted, this tool is expected to aid in
suggesting improved drug protocols for the individual or for
a population of patients. Human trials are warranted for
testing the suggested improved TPO protocol, possibly in
conjunction with chemotherapy.
ACKNOWLEDGMENTS
We are much obliged to Stanimir Vuk-Pavlovic for stimu-
lating discussions and to Yuri Kogan for important help in
the mathematical modelling. The work was supported by
the Chai Foundation, the Dutch Organization for the
Advancement of Research NWO, section of Medical and
Health Sciences ZonMW and contracts of the Commission of
the European Communities. We acknowledge the generous
contribution of mouse and Rhesus monkey recombinant
TPO by Genentech Inc., South San Francisco, CA, USA (Dr
DL Eaton).
Validation of Thrombopoiesis Drug Response Predictions 689
 2003 Blackwell Publishing Ltd, British Journal of Haematology 123: 683–691
REFERENCES
Agur, Z., Arnon, R. & Schechter, B. (1988) Reduction of cytotoxi-
city to normal tissues by new regimens of phase-specific drugs.
Mathematical Biosciences, 92, 1–15.
Agur, Z., Arnon, R., Sandak, B. & Schechter, B. (1991) Zidovudine
toxicity to murine bone marrow may be affected by the exact
frequency of drug administration. Experimental Hematology, 19,
364–368.
Arnold, J.T., Daw, N.C., Stenberg, P.E., Jayawardene, D., Srivastava,
D.K. & Jackson, C.W. (1997) A single injection of pegylated
murine megakaryocyte growth and development factor (MGDF)
into mice is sufficient to produce a profound stimulation of
megakaryocyte frequency, size, and ploidization. Blood, 89, 823–
833.
Basser, R. (2002) The impact of thrombopoietin on clinical practice.
Current Pharmaceutical Design, 8, 369–377.
Brent, R.P. (1973) Algorithms for Minimization Without Derivatives.
Prentice-Hall, Englewood Cliffs, NJ.
Daw, N.C., Arnold, J.T., Abushullaih, B.A., Stenberg, P.E., White,
M.M., Jayawardene, D., Srivastava, D.K. & Jackson, C.W. (1998)
A single intravenous dose of murine megakaryocyte growth and
development factor potently stimulates platelet production,
challenging the necessity for daily administration. Blood, 91,
466–474.
De Serres, M., Yeager, R.L., Dillberger, J.E., Lalonde, G., Gardner,
G.H., Rubens, C.A., Simkins, A.H., Sailstad, J.M., McNulty, M.J. &
Woolley, J.L. (1999) Pharmacokinetics and hematological effects
of the pegylated thrombopoietin peptide mimetic GW395058 in
rats and monkeys after intravenous or subcutaneous adminis-
tration. Stem Cells, 17, 316–326.
Demetri, G.D. (2001) Targeted approaches for the treatment of
thrombocytopenia. The Oncologist, 6(Suppl. 5), 15–23.
Ebbe, S. & Stohlman, F. (1965) Megakaryocytopoiesis in the rat.
Blood, 26, 20–35.
Elting, L.S., Rubenstein, E.B., Martin, C.G., Kurtin, D., Rodriguez, S.,
Laiho, E., Kanesan, K., Cantor, S.B. & Benjamin, R.S. (2001)
Incidence, cost, and outcomes of bleeding and chemotherapy
dose modification among solid tumor patients with chemother-
apy-induced thrombocytopenia. Journal of Clinical Oncology, 19,
1137–1146.
Farese, A.M., Hunt, P., Boone, T. & MacVittie, T.J. (1995)
Recombinant human megakaryocyte growth and development
factor stimulates thrombopoiesis in normal nonhuman primates.
Blood, 86, 54–59.
Harker, L.A. (1999) Physiology and clinical applications of platelet
growth factors. Current Opinion in Hematology, 6, 127–134.
Harker, L.A., Hunt, P., Marzec, U.M., Kelly, A.B., Tomer, A.,
Hanson, S.R. & Stead, R.B. (1996a) Regulation of platelet
production and function by megakaryocyte growth and devel-
opment factor in nonhuman primates. Blood, 87, 1833–1844.
Harker, L.A., Marzec, U.M., Hunt, P., Kelly, A.B., Tomer, A.,
Cheung, E., Hanson, S.R. & Stead, R.B. (1996b) Dose-response
effects of pegylated human megakaryocyte growth and develop-
ment factor of platelet production and function in nonhuman
primates. Blood, 88, 511–521.
Haznedaroglu, I.C., Goker, H., Turgut, M., Buyukasik, Y. & Benekli,
M. (2002) Thrombopoietin as a drug: biologic expectations,
clinical realities, and future directions. Clinical and Applied
Thrombosis/Hemostasis, 8, 193–212.
Kabaya, K., Akahori, H., Shibuya, K., Nitta, Y., Ida, M., Kusaka, M.,
Kato, T. & Miyazaki, H. (1996) In vivo effects of pegylated
recombinant human megakaryocyte growth and development
factor on hematopoiesis in normal mice. Stem Cells, 14, 651–660.
Kaushansky, K., Lin, N., Grossman, A., Humes, J., Sprugel, K.H. &
Broudy, V.C. (1996) Thrombopoietin expands erythroid, granu-
locyte-macrophage, and megakaryocytic progenitor cells in nor-
mal and myelosuppressed mice. Experimental Hematology, 24,
265–269.
Luoh, S., Stephanich, E., Solar, G., Steinmetz, H., Lipari, T., Pestina,
T.I., Jackson, C.W. & de Sauvage, F.J. (2000) Role of the distal
half of the c-Mpl intracellular domain in control of platelet pro-
duction by thrombopoietin in vivo. Molecular and Cellular Biology,
20, 507–515.
Miyazaki, M., Fujiwara, Y., Isobe, T., Yamakido, M., Kato, T. &
Miyazaki, H. (1999) The relationship between carboplatin AUC
and serum TPO kinetics in patients with lung cancer. Anticancer
Research, 19, 667–670.
Neelis, K.J., Qingliang, L., Thomas, G.R., Cohen, B.L., Eaton, D.L. &
Wagemaker, G. (1997a) Prevention of thrombocytopenia by
thrombopoietin in myelosuppressed rhesus monkeys accom-
panied by prominent erythropoietic stimulation and iron deple-
tion. Blood, 90, 58–63.
Neelis, K.J., Hartong, S.C., Egeland, T., Thomas, G.R., Eaton, D.L. &
Wagemaker, G. (1997b) The efficacy of single-dose administra-
tion of thrombopoietin with co-administration of either granu-
locyte/macrophage or granulocyte colony-stimulating factor in
myelosuppressed rhesus monkeys. Blood, 90, 2565–2573.
Neelis, K.J., Visser, T.P., Dimjati, W., Thomas, G.R., Fielder, P.J.,
Bloedow, D., Eaton, D.L. & Wagemaker, G. (1998) A single dose
of TPO shortly after myelosuppressive total body irradiation
prevents pancytopenia in mice by promoting short-term multi-
lineage spleen-repopulating cells at the transient expense of bone
marrow-repopulating cells. Blood, 92, 1586–1597.
Press, W.H., Flannery, B.P., Teukolsky, S.A. & Vetterling, W.T.
(1993) Numerical Recipes in C: The Art of Scientific Computing.
Cambridge University Press, Cambridge, UK.
Schermer, S. (1967) The Blood Morphology of Laboratory Animals.
F.A. Davis Co., Philadelphia, PE.
Siegers, M.P., Feinendegen, L.E., Lahiri, S.K. & Cronkite, E.P. (1979)
Relative number and proliferation kinetics of hemopoietic stem
cells in the mouse. Blood cells, 5, 211–236.
Skomorovski, K. & Agur, Z. (2001) A new method for predicting
and optimizing thrombopoietin (TPO) therapeutic protocols in
thrombocytopenic patients and in platelet donors [abstract]. The
Hematology Journal, 1(Suppl. 1), 185.
Sola, M.C., Christensen, R.D., Hutson, A.D. & Tarantal, A.F. (2000)
Pharmacokinetics, pharmacodynamics, and safety of adminis-
tering pegylated recombinant megakaryocyte growth and devel-
opment factor to newborn rhesus monkeys. Pediatric Research,
47, 208–214.
Ubezio, P., Tagliabue, G., Schechter, B. & Agur, Z. (1994)
Increasing 1-beta-D-arabinofuranosylcytosine efficacy by sched-
uled dosing intervals based on direct measurements of bone
marrow cell kinetics. Cancer Research, 54, 6446–6451.
Ulich, T.R., del Castillo, J., Senaldi, G., Cheung, E., Roskos, L.,
Young, J., Molineux, G., Guo, J., Schoemperlen, J., Munyakazi, L.,
Murphy-Filkins, R., Tarpley, J.E., Toombs, C.F., Kaufman, S., Yin,
S., Nelson, A.G., Nichol, J.L. & Sheridan, W.P. (1999) Mega-
karyocytopoiesis: the prolonged hematologic effects of a single
injection of PEG-rHuMGDF in normal and thrombocytopenic
mice. Experimental Hematology, 27, 117–130.
Vadhan-Raj, S. (1998) Recombinant human TPO: clinical experi-
ence and in vivo biology. Seminars in Hematology, 35, 261–268.
Vadhan-Raj, S., Murray, L.J., Bueso-Ramos, C., Patel, S., Reddy,
S.P., Hoots, W.K., Johnston, T., Papadopolous, N.E., Hittelman,
W.N., Johnston, D.A., Yang, T.A., Paton, V.E., Cohen, R.L.,
Hellmann, S.D., Benjamin, R.S. & Broxmeyer, H.E. (1997) Sti-
690 K. Skomorovski et al
 2003 Blackwell Publishing Ltd, British Journal of Haematology 123: 683–691
mulation of megakaryocyte and platelet production by a single
dose of recombinant human TPO in patients with cancer. Annals
of Internal Medicine, 126, 673–681.
Wagemaker, G., Hartong, S.C., Neelis, K.J., Egeland, T. & Wognum,
A.W. (1998) In vivo expansion of hemopoietic stem cells. Stem
Cells, 16(Suppl. 1), 185–191.
Validation of Thrombopoiesis Drug Response Predictions 691
 2003 Blackwell Publishing Ltd, British Journal of Haematology 123: 683–691
